DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics.

Author(s): Gridelli C, Rossi A, Morgillo F, Bareschino MA, Maione P, Di Maio M, Ciardiello F

Affiliation(s): Division of Medical Oncology, S.G. Moscati Hospital, Citta Ospedaliera, Contrada Amoretta, Avellino, Italy. cgridelli@libero.it

Publication date & source: 2007-11, Clin Lung Cancer., 8(9):568-71.

Publication type: Clinical Trial, Phase II; Randomized Controlled Trial

In the current clinical trial summary, we present a randomized phase II trial of pemetrexed or RAD001 as second-line treatment of elderly patients with advanced non-small-cell lung cancer. The molecular and clinical rationale is reviewed. The primary endpoint is progression-free survival, and secondary endpoints include objective tumor response rates, disease control rates, safety, tolerability, and overall survival. Based on the statistical design, the investigators plan to enroll 92 elderly patients, 46 per arm.

Page last updated: 2008-03-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017